Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steve Chen

Diagnostic Radiology Seattle, WA Medical Doctor

NPI 1316924533 CMS profile 286872

500 17Th Ave, Seattle, WA 98122

Open in the dashboard

General payments

$281,142

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steve Chen of Seattle, WA is reported in the CMS Open Payments database as having received $281,142 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,749 35
2024 General $31,544 70
2023 General $9,359 31
2022 General $198,254 49
2021 General $27,345 17
2020 General $253 4
2019 General $4,638 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steve Chen
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Steve Chen were reported at $9,749. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Steve Chen Diagnostic Radiology median Middle half National median
2019 $4,638 $108 $29–$318 $163
2020 $253 $65 $21–$252 $114
2021 $27,345 $92 $24–$292 $132
2022 $198,254 $104 $29–$294 $149
2023 $9,359 $110 $29–$337 $160
2024 $31,544 $113 $30–$356 $164
2025 $9,749 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $253,849 60 payments
  2. Boston Scientific Corporation $13,415 39 payments
  3. Terumo Medical Corporation $5,736 13 payments
  4. Surefire Medical, Inc. $2,299 10 payments
  5. Inari Medical, Inc. $1,500 28 payments
  6. Route 92 Medical, Inc. $776 2 payments
  7. Penumbra, Inc. $506 9 payments
  8. AngioDynamics, Inc. $426 5 payments
  9. Instylla Inc. $418 3 payments
  10. Medtronic, Inc. $307 7 payments
  11. Other $1,910 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $255,750 27 payments
  2. Consulting Fee $11,250 5 payments
  3. Food and Beverage $10,153 184 payments
  4. Travel and Lodging $2,788 10 payments
  5. Honoraria $1,200 1 payment
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $253,692 58 payments
  2. TR Band $3,649 4 payments
  3. Navicross $3,637 3 payments
  4. Glidesheath $3,619 2 payments
  5. GlideWire $3,619 2 payments
  6. TheraSphere Y90 Glass Microspheres 10 GBq $2,700 1 payment
  7. TRINAV INFUSION SYSTEM $2,299 10 payments
  8. GENERAL PAIN MANAGEMENT $2,250 1 payment
  9. Azur CX Detachable $1,950 7 payments
  10. HydroPearl $1,782 4 payments
  11. Other $13,870 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

24

Median for Interventional Radiology: 38

Drug cost

$103

Median for Interventional Radiology: $333

Branded share of claims

0%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin Hcl Generic 12 $74
Pantoprazole Sodium Generic 12 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$320,604

Of which drugs: $222

Medicare patients

283

Average age 72

Services billed

3,341

135 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 50%
Arthritis 49%
Ischemic heart disease 46%
Diabetes 43%
Atrial fibrillation 35%
Heart failure 34%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 23 2,203 $222

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record